EXEL

Exelixis Inc. (EXEL) | Rumor.io

Exelixis

EXEL

Attention (50-day avg)0%

Attention rank (50-day avg)#1,212

Bullish sentiment (50-day avg)90%

Price to earnings ratio18.4

Market capitalization14.5B

Earnings per share3.18

Dividend yield (TTM)—

Revenue (annual)2.3B

Net income (annual)782.6M

Social

What share of all stock conversation is about EXEL?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% -0.03	0% +0	0% +0	0% 0

Sep 11

The FDA has extended the review period for Exelixis' experimental colorectal cancer drug combination by three months, citing a major amendment based on updated safety and efficacy data.
Exelixis' cancer drug zanzalintinib, in combination with atezolizumab, is expected to receive approval with an extended label based on the FDA's decision to extend the review period.
Exelixis' stock price fell 3.5% premarket after the FDA's announcement, with analysts maintaining a positive outlook on the company's prospects for zanzalintinib's approval.

Generated by AI

Sentiment

Of the messages about EXEL that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% 0	100%	87.32% -12.68	87.5% +2.13
Bearish	0% 0	0%	12.68% +12.68	12.5% -2.13

Bullish· Jun 23

Exelixis' ($EXEL) zanzalintinib in combination with atezolizumab (Tecentriq) demonstrated a statistically significant overall survival benefit in the combination in patients with a type of metastatic colorectal cancer.
The STELLAR-303 phase 3 pivotal trial results led to a 27.59% surge in $EXEL shares, with a 6.7% gap up and strong breakaway momentum.
Exelixis ($EXEL) has shown two quarters of explosive earnings growth, with EPS up 353% Q/Q, and a short ratio of 6.12, priming for a potential short squeeze.

Bearish· Jun 28

The management team's performance is questionable, with some investors expressing regret over their investment decision and others criticizing the company's leadership as "greedy".
Exelixis' recent interim Cabozantinib combination result was disappointing, leading to a significant drop in the company's stock price and market capitalization.
The company's stock price is approaching its 52-week low, with some investors expecting it to trade at a lower price-to-earnings ratio in the future, potentially jeopardizing its premium valuation.

Generated by AI

Topics

Of the messages about EXEL that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	100%	14.63%	19.46%
Announcements	—	0%	75.61%	65.5%
Earnings	—	0%	0%	2.91%
Controversies	—	0%	9.76%	0.7%
Analysts	—	0%	0%	11.43%
Macro	—	0%	0%	0%

Earnings· Oct 30

Exelixis, Inc. (EXEL) reported Q3 adjusted EPS of 34c, beating consensus by 15c and revenue of $271.7M, beating consensus by $43.53M.
The company sees a FY19 effective tax rate of 21-23%.
EXEL's earnings report beat Estimize consensus by 8c for EPS and $37.56M for revenue.

Analysts· Jan 13

SunTrust initiates coverage of EXEL with a Buy rating and $31 price target.
Analysts are very confident about EXEL, with a 87% buy percentage consensus.
EXEL's lead asset Cabometyx has a potentially "best-in-class" profile, with ample catalysts expected to unlock its value in the next 18 months.

Announcements· Oct 20

Exelixis ($EXEL) announced detailed results from the Phase 3 STELLAR-303 pivotal trial evaluating zanzalintinib in combination with an immune checkpoint inhibitor in metastatic colorectal cancer.
The trial showed that zanzalintinib + Tecentriq cut death risk by 20% in advanced colorectal cancer, with FDA filing planned for 2025.
BofA reduced its forecast and price target for zanzalintinib to $43, citing a potential niche role for the treatment in colorectal cancer.

Technical Analysis· Sep 29

$EXEL is testing the upper Bollinger Band and the 50 SMA, which is considered a bullish sign.
The stock has found support at prior highs of 11.96 and 12.26, which are crucial levels, and buyers may step in at $11.44, the 50 SMA.
The weekly and daily charts show a long way down for $EXEL, but a small bounce is possible, and a reversal is needed to confirm at 12.20 or higher.

Generated by AI

Community

Of the messages about EXEL, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	99.45%	61.16%	61.92%
Newcomers	0%	0.55%	38.84%	38.08%

Regulars· Nov 4

$EXEL is considered "way too cheap" and has the potential to print 45 or reach an all-time high without the recent hiccup.
The Q3 2025 earnings announcement for $EXEL beat estimates, with adj. EPS at $0.78, a 66.0% YoY increase, and revenue at $597.8M, a 10.8% YoY increase.
Exelixis has crushed earnings estimates and lifted guidance on strong CABOMETYX sales, according to Q3 2025 financial results and corporate update.

Newcomers· Sep 9

Newcomers to the Exelixis, Inc. stock are focused on the company's reliance on a single product, cabozantinib, which accounts for nearly all of their revenue.
The stock's valuation is a concern, with a market cap of $15 billion and annual revenue of $2 billion, leading some to believe it may be overvalued.
The potential impact of a generic version of cabozantinib on Exelixis' stock price is being discussed, with some considering the possibility that it could lead to a loss of 10-20% in revenue.

Generated by AI

Exelixis (NasdaqGS: EXEL) said the FDA has extended its review of zanzalintinib plus atezolizumab for metastatic colorectal cancer. The agency lengthened the decision timeline after Exelixis submitted a major amendment with updated safety and efficacy data. The extended FDA review tied to new zanzalintinib safety and efficacy information only captures part of what matters today. Check out 4 other big wins that Exelixis investors should know about. To put this regulatory update in context,...

8d agoYahoo Finance

Exelixis Eyes Oncology Deals, Readies Zanzalintinib Launch as Cabozantinib Tops $3B

Exelixis (NASDAQ:EXEL) President and CEO Michael Morrissey said the company is focused on expanding its oncology franchises through internal development, selective business development and potential collaborations, while preparing for a planned launch of zanzalintinib in metastatic colorectal cancer

12d agoYahoo Finance

Exelixis (EXEL) Faces a Three-Month Zanzalintinib Review Extension. Can the Data Support Approval?

Exelixis, Inc. (NASDAQ:EXEL) disclosed in a September 11 filing that the FDA had extended the review of zanzalintinib by three months, setting a new target action date of March 3, 2027. The September 10 notification followed an FDA request for updated safety and efficacy information. The submitted data were classified as a major amendment. The […]

13d agoYahoo Finance Singapore

Exelixis Eyes Zanza Launch as CABOMETYX Growth Faces NET Ramp Hurdle

Exelixis (NASDAQ:EXEL) executives outlined plans to continue expanding the CABOMETYX franchise while preparing for a potential launch of zanzalintinib, or zanza, in colorectal cancer later this year. Speaking at a Wells biotech session, Chief Financial Officer Chris Senner said the company is worki

15d agoYahoo Finance

Citizens reiterates Exelixis stock rating on FDA review extension

15d agoInvesting.com

Exelixis: Why The 3-Month Delay Is More Negative Than It May Seem (Downgrade)

15d agoSeeking Alpha

Also Discussed

Investors talking about EXEL also mention

#	Name	Attention
1	Acadia Pharmaceuticals Inc.ACAD	0%+0
2	XOMA CorporationXOMA	0%0
3	Sarepta Therapeutics, Inc.SRPT	0%-0.01
4	FOLD - Amicus Therapeutics, Inc.	——
5	Ironwood Pharmaceuticals, Inc. Class A Common StockIRWD	0%new
6	SGEN - Seagen Inc.	——
7	Incyte Corp.INCY	0%new
8	Amarin Corporation plc ADRAMRN	0%+0
9	Celldex Therapeutics IncCLDX	0%0
10	HZNP - Horizon Therapeutics Public Limited Company	——

Exelixis Inc.

Healthcare
Biotechnology

Exelixis Inc. is an oncology-focused biopharmaceutical company that discovers, develops, and commercializes medicines for difficult-to-treat cancers. The company’s current portfolio centers on cancer therapies built around cabozantinib, including CABOMETYX and COMETRIQ, which are used across multiple tumor types in clinical practice. Exelixis also advances a broader pipeline of small-molecule and biotherapeutic candidates aimed at expanding treatment options in solid tumors and other oncology settings. In addition to internal drug development, the company works through collaborations to support research, development, and commercialization activities. Based in Alameda, California, Exelixis plays a significant role in the cancer treatment market by combining approved products with an active development pipeline focused on targeted oncology medicines.

Website

Location

1851 Harbor Bay Parkway

Alameda, CA, 94502

United States

Social

What share of all stock conversation is about EXEL?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% -0.03	0% +0	0% +0	0% 0

Sep 11

The FDA has extended the review period for Exelixis' experimental colorectal cancer drug combination by three months, citing a major amendment based on updated safety and efficacy data.
Exelixis' cancer drug zanzalintinib, in combination with atezolizumab, is expected to receive approval with an extended label based on the FDA's decision to extend the review period.
Exelixis' stock price fell 3.5% premarket after the FDA's announcement, with analysts maintaining a positive outlook on the company's prospects for zanzalintinib's approval.

Generated by AI

Sentiment

Of the messages about EXEL that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% 0	100%	87.32% -12.68	87.5% +2.13
Bearish	0% 0	0%	12.68% +12.68	12.5% -2.13

Bullish· Jun 23

Exelixis' ($EXEL) zanzalintinib in combination with atezolizumab (Tecentriq) demonstrated a statistically significant overall survival benefit in the combination in patients with a type of metastatic colorectal cancer.
The STELLAR-303 phase 3 pivotal trial results led to a 27.59% surge in $EXEL shares, with a 6.7% gap up and strong breakaway momentum.
Exelixis ($EXEL) has shown two quarters of explosive earnings growth, with EPS up 353% Q/Q, and a short ratio of 6.12, priming for a potential short squeeze.

Bearish· Jun 28

The management team's performance is questionable, with some investors expressing regret over their investment decision and others criticizing the company's leadership as "greedy".
Exelixis' recent interim Cabozantinib combination result was disappointing, leading to a significant drop in the company's stock price and market capitalization.
The company's stock price is approaching its 52-week low, with some investors expecting it to trade at a lower price-to-earnings ratio in the future, potentially jeopardizing its premium valuation.

Generated by AI

Topics

Of the messages about EXEL that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	100%	14.63%	19.46%
Announcements	—	0%	75.61%	65.5%
Earnings	—	0%	0%	2.91%
Controversies	—	0%	9.76%	0.7%
Analysts	—	0%	0%	11.43%
Macro	—	0%	0%	0%

Earnings· Oct 30

Exelixis, Inc. (EXEL) reported Q3 adjusted EPS of 34c, beating consensus by 15c and revenue of $271.7M, beating consensus by $43.53M.
The company sees a FY19 effective tax rate of 21-23%.
EXEL's earnings report beat Estimize consensus by 8c for EPS and $37.56M for revenue.

Analysts· Jan 13

SunTrust initiates coverage of EXEL with a Buy rating and $31 price target.
Analysts are very confident about EXEL, with a 87% buy percentage consensus.
EXEL's lead asset Cabometyx has a potentially "best-in-class" profile, with ample catalysts expected to unlock its value in the next 18 months.

Announcements· Oct 20

Exelixis ($EXEL) announced detailed results from the Phase 3 STELLAR-303 pivotal trial evaluating zanzalintinib in combination with an immune checkpoint inhibitor in metastatic colorectal cancer.
The trial showed that zanzalintinib + Tecentriq cut death risk by 20% in advanced colorectal cancer, with FDA filing planned for 2025.
BofA reduced its forecast and price target for zanzalintinib to $43, citing a potential niche role for the treatment in colorectal cancer.

Technical Analysis· Sep 29

$EXEL is testing the upper Bollinger Band and the 50 SMA, which is considered a bullish sign.
The stock has found support at prior highs of 11.96 and 12.26, which are crucial levels, and buyers may step in at $11.44, the 50 SMA.
The weekly and daily charts show a long way down for $EXEL, but a small bounce is possible, and a reversal is needed to confirm at 12.20 or higher.

Generated by AI

Community

Of the messages about EXEL, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	99.45%	61.16%	61.92%
Newcomers	0%	0.55%	38.84%	38.08%

Regulars· Nov 4

$EXEL is considered "way too cheap" and has the potential to print 45 or reach an all-time high without the recent hiccup.
The Q3 2025 earnings announcement for $EXEL beat estimates, with adj. EPS at $0.78, a 66.0% YoY increase, and revenue at $597.8M, a 10.8% YoY increase.
Exelixis has crushed earnings estimates and lifted guidance on strong CABOMETYX sales, according to Q3 2025 financial results and corporate update.

Newcomers· Sep 9

Newcomers to the Exelixis, Inc. stock are focused on the company's reliance on a single product, cabozantinib, which accounts for nearly all of their revenue.
The stock's valuation is a concern, with a market cap of $15 billion and annual revenue of $2 billion, leading some to believe it may be overvalued.
The potential impact of a generic version of cabozantinib on Exelixis' stock price is being discussed, with some considering the possibility that it could lead to a loss of 10-20% in revenue.

Generated by AI

Exelixis

Social

Sep 11

Bullish· Jun 23

Bearish· Jun 28

Earnings· Oct 30

Analysts· Jan 13

Announcements· Oct 20

Technical Analysis· Sep 29

Regulars· Nov 4

Newcomers· Sep 9

Exelixis (EXEL) Gets FDA Review Extension For Zanzalintinib განაცხად tometastatic Colorectal Cancer

Exelixis Eyes Oncology Deals, Readies Zanzalintinib Launch as Cabozantinib Tops $3B

Exelixis (EXEL) Faces a Three-Month Zanzalintinib Review Extension. Can the Data Support Approval?

Exelixis Eyes Zanza Launch as CABOMETYX Growth Faces NET Ramp Hurdle

Citizens reiterates Exelixis stock rating on FDA review extension

Exelixis: Why The 3-Month Delay Is More Negative Than It May Seem (Downgrade)

Also Discussed

Exelixis Inc.

Company Information

Location

Exelixis (EXEL) Gets FDA Review Extension For Zanzalintinib განაცხად tometastatic Colorectal Cancer

Exelixis Eyes Oncology Deals, Readies Zanzalintinib Launch as Cabozantinib Tops $3B

Exelixis (EXEL) Faces a Three-Month Zanzalintinib Review Extension. Can the Data Support Approval?

Exelixis Eyes Zanza Launch as CABOMETYX Growth Faces NET Ramp Hurdle

Citizens reiterates Exelixis stock rating on FDA review extension

Exelixis: Why The 3-Month Delay Is More Negative Than It May Seem (Downgrade)

Also Discussed

Social

Sep 11

Bullish· Jun 23

Bearish· Jun 28

Earnings· Oct 30

Analysts· Jan 13

Announcements· Oct 20

Technical Analysis· Sep 29

Regulars· Nov 4

Newcomers· Sep 9